C. Bucci-Rechtweg

发表

Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders

K. Romero, V. Sinha, F. Johnson, 2019, Orphanet Journal of Rare Diseases.

Enhancing the Pediatric Drug Development Framework to Deliver Better Pediatric Therapies Tomorrow.

C. Bucci-Rechtweg, 2017, Clinical therapeutics.

Pediatric Extrapolation in Type 2 Diabetes: Future Implications of a Workshop

S. Y. Amy Cheung, J. Barrett, C. Bucci-Rechtweg, 2020, Clinical pharmacology and therapeutics.

Challenges and Opportunities in the Development of Medical Therapies for Pediatric Populations and the Role of Extrapolation

J. Barrett, Jing Liu, C. Bucci-Rechtweg, 2018, Clinical pharmacology and therapeutics.

Applying Regulatory Science to Develop Safe and Effective Medicines for Neonates: Report of the US Food and Drug Administration First Annual Neonatal Scientific Workshop, October 28–29, 2014

J. Davis, V. Sinha, M. Offringa, 2015, Therapeutic innovation & regulatory science.

Reduction in the risk of clinical fractures after a single dose of zoledronic Acid 5 milligrams.

S. Boonen, I. Reid, R. Eastell, 2013, The Journal of clinical endocrinology and metabolism.

Subtrochanteric Fractures in Bisphosphonate-Naive Patients: Results from the HORIZON-Recurrent Fracture Trial

S. Boonen, C. Pieper, J. Magaziner, 2011, Calcified Tissue International.

Once‐Yearly Zoledronic Acid in Older Men Compared with Women with Recent Hip Fracture

R. Rizzoli, S. Boonen, J. Kaufman, 2011, Journal of the American Geriatrics Society.

Inclusion of pregnant and breastfeeding women in research – efforts and initiatives

C. Bucci-Rechtweg, Catherine M Sherwin, S. Illamola, 2018, British journal of clinical pharmacology.

A single infusion of zoledronic acid produces sustained remissions in paget disease: Data to 6.5 years

Jacques P. Brown, I. Reid, P. Miller, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Inclusion of Adolescents in Adult Clinical Trials: Report of the Institute for Advanced Clinical Trials for Children’s Pediatric Innovation Research Forum

Carmen Moreno, R. Portman, G. Noel, 2021, Therapeutic Innovation & Regulatory Science.

Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.

J. Reginster, P. Sambrook, D. Reid, 2013, Rheumatology.

The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program.

D. Reid, D. Black, E. Orwoll, 2010, Journal of the American Dental Association.

Improving Development of Drug Treatments for Pregnant Women and the Fetus

A. David, S. Thornton, C. Bucci-Rechtweg, 2022, Therapeutic Innovation & Regulatory Science.

Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis

P. Sambrook, D. Reid, K. Saag, 2012, Osteoporosis International.

ZOLEDRONOVAYa KISLOTA V PROFILAKTIKE POTERI KOSTNOY TKANI U zhENShchIN POSTMENOPAUZAL'NOGO VOZRASTA S OSTEOPENIEY

C. Benhamou, P. Miller, P. Mesenbrink, 2011 .

Evaluation of the Safety of Drugs and Biological Products Used During Lactation: Workshop Summary

C. Chambers, M. Tassinari, S. Ito, 2017, Clinical pharmacology and therapeutics.

Scientific, ethical, and legal considerations for the inclusion of pregnant people in clinical trials

A. Lyerly, G. Baer, C. Bucci-Rechtweg, 2022, American Journal of Obstetrics and Gynecology.

Fracture risk and zoledronic acid therapy in men with osteoporosis.

J. Reginster, R. Rizzoli, S. Boonen, 2012, The New England journal of medicine.

Translating Discovery into Cures for Children with Cancer Childhood Cancer Research Landscape Report

Nancy F. Lenfestey, A. Jemal, K. Miller, 2016 .

Tiny and Forgotten: A Call for Focused Neonatal Policy Reform

R. Ward, C. Bucci-Rechtweg, 2019, Therapeutic innovation & regulatory science.

Association between timing of zoledronic acid infusion and hip fracture healing

S. Boonen, J. Magaziner, L. Nordsletten, 2011, Osteoporosis International.

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

Michael P. Kelly, S. Boonen, J. Cauley, 2010, The New England journal of medicine.

Predictors of new and severe vertebral fractures: results from the HORIZON Pivotal Fracture Trial

L. Palermo, D. Black, S. Burch, 2011, Osteoporosis International.

The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment of Osteoporosis: A Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT)

S. Cummings, S. Boonen, J. Cauley, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass: A Randomized Controlled Trial

C. Benhamou, P. Mesenbrink, M. McClung, 2009, Obstetrics and gynecology.

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis

S. Boonen, P. Miller, E. Eriksen, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Efficacy and safety of a once‐yearly i.v. Infusion of zoledronic acid 5 mg versus a once‐weekly 70‐mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double‐blind, active‐controlled study

Jacques P. Brown, J. Adachi, E. Orwoll, 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Clinical Risk Factors for Recurrent Fracture after Hip Fracture: A Prospective Study

S. Boonen, C. Pieper, J. Magaziner, 2011, Calcified Tissue International.

Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.

J. Reginster, P. Sambrook, D. Reid, 2010, Bone.

Subgroup Variations in Bone Mineral Density Response to Zoledronic Acid After Hip Fracture

S. Boonen, C. Pieper, J. Magaziner, 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON–Recurrent Fracture Trial

S. Boonen, C. Pieper, J. Magaziner, 2011, Osteoporosis International.

The culture of research communication in neonatal intensive care units: key stakeholder perspectives

Elissa Z. Faro, R. Ariagno, J. Aschner, 2021, Journal of Perinatology.

Extrapolation as a Default Strategy in Pediatric Drug Development

Freda Cooner, C. Bucci-Rechtweg, H. Thackray, 2022, Therapeutic Innovation & Regulatory Science.

The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

S. Cummings, S. Boonen, J. Cauley, 2011 .

Intravenous zoledronic acid (ZOL) compared to IV pamidronate (PAM) in children with severe osteogenesis imperfecta (OI)

I. Kaitila, F. Glorieux, H. Plotkin, 2008 .

Strategies to facilitate adolescent access to medicines: Improving regulatory guidance

R. Nelson, C. Bucci-Rechtweg, M. Gamalo, 2022, Clinical trials.

COMMENTARY Inclusion of pregnant and breastfeeding women in research – efforts and initiatives

C. Bucci-Rechtweg, A. Zajicek, M. Costantine, 2018 .